京东健康(06618.HK)公开发售获421.91倍认购 发售价定为70.58港元/股
格隆汇 12 月 7日丨京东健康(06618.HK)发布公告，公司全球发售3.819亿股股份，其中香港发售股份4200.9万股，国际发售股份3.39891亿股，另有15%超额配股权；发售价已厘定为每股发售股份70.58港元，每手买卖单位50股；BofA SECURITIES、海通国际及UBS为联席保荐人，预期股份将于2020年12月8日于联交所主板挂牌上市。
香港公开发售项下初步可供认购的香港发售股份已获极大幅超额认购。合共接获846,209份有效申请，认购合共约80.56亿股发售股份，相当于香港公开发售项下初步可供认购的香港发售股份总数约421.91倍。国际发售项下初步提呈发售的发售股份已获大幅超额认购，相当于国际发售项下初步可供认购发售股份总数的约31.1倍。
根据与基石投资者的基石投资协议，基石投资者认购的发售股份数目现已厘定。 Hillhouse认购1658.4万股，Tiger Global认购3295.225万股，Lake Bleu Prime认购1098.405万股，中国国有企业结构调整基金认购2188.205万股，GIC认购3844.43万股以及贝莱德认购2746.02万股发售股份，约占(i)全球发售项下初步可供认购的发售股份的38.83%(假设超额配股权未获行使)；及(ii)紧随全球发售完成后(假设超额配股权未获行使且不计根据首次公开发售前员工股权激励计划、首次公开发售后购股权计划及首次公开发售后股份奖励计划将予发行的股份)公司已发行股本总额的4.74%。
按发售价每股发售股份70.58港元计算，假设超额配股权未获行使，全球发售募集资金净额预计约为264.57亿港元。其中，约40%募集资金净额预计在未来36至60个月将用于业务扩张；约30%募集资金净额预计在未来24至36个月将用于研发；约20%募集资金净额预计将用于潜在投资及收购或战略联盟；及约10%募集资金净额预计将用于营运资金及一般公司用途。倘超额配股权获悉数行使，公司将就超额配股权获行使后拟发行的5728.5万股发售股份收取额外募集资金净额约39.82亿港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
